Progressive Renal Disease Established by Renin-Coding Adeno-Associated Virus-Driven Hypertension in Diverse Diabetic Models

J Am Soc Nephrol. 2018 Feb;29(2):477-491. doi: 10.1681/ASN.2017040385. Epub 2017 Oct 23.

Abstract

Progress in research and developing therapeutics to prevent diabetic kidney disease (DKD) is limited by a lack of animal models exhibiting progressive kidney disease. Chronic hypertension, a driving factor of disease progression in human patients, is lacking in most available models of diabetes. We hypothesized that superimposition of hypertension on diabetic mouse models would accelerate DKD. To test this possibility, we induced persistent hypertension in three mouse models of type 1 diabetes and two models of type 2 diabetes by adeno-associated virus delivery of renin (ReninAAV). Compared with LacZAAV-treated counterparts, ReninAAV-treated type 1 diabetic Akita/129 mice exhibited a substantial increase in albumin-to-creatinine ratio (ACR) and serum creatinine level and more severe renal lesions. In type 2 models of diabetes (C57BKLS db/db and BTBR ob/ob mice), compared with LacZAAV, ReninAAV induced significant elevations in ACR and increased the incidence and severity of histopathologic findings, with increased serum creatinine detected only in the ReninAAV-treated db/db mice. The uninephrectomized ReninAAV db/db model was the most progressive model examined and further characterized. In this model, separate treatment of hyperglycemia with rosiglitazone or hypertension with lisinopril partially reduced ACR, consistent with independent contributions of these disorders to renal disease. Microarray analysis and comparison with human DKD showed common pathways affected in human disease and this model. These results identify novel models of progressive DKD that provide researchers with a facile and reliable method to study disease pathogenesis and support the development of therapeutics.

Keywords: chronic diabetic complications; diabetic glomerulopathy; diabetic nephropathy; electron microscopy; hypertension.

MeSH terms

  • Animals
  • Antihypertensive Agents / therapeutic use
  • Creatinine / blood
  • Dependovirus
  • Diabetes Mellitus, Type 1 / complications*
  • Diabetes Mellitus, Type 1 / drug therapy
  • Diabetes Mellitus, Type 2 / complications*
  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetic Nephropathies / blood
  • Diabetic Nephropathies / etiology*
  • Diabetic Nephropathies / pathology
  • Disease Models, Animal*
  • Disease Progression
  • Female
  • Genetic Vectors
  • Hypertension / complications*
  • Hypertension / drug therapy
  • Hypertension / genetics
  • Hypoglycemic Agents / therapeutic use
  • Janus Kinases / metabolism
  • Lac Operon / genetics
  • Lisinopril / therapeutic use
  • Male
  • Mice
  • Nephrectomy
  • Nitric Oxide Synthase Type III / genetics
  • Renin / genetics*
  • Rosiglitazone / therapeutic use
  • STAT Transcription Factors / metabolism
  • Serum Albumin / metabolism
  • Severity of Illness Index
  • Signal Transduction

Substances

  • Antihypertensive Agents
  • Hypoglycemic Agents
  • STAT Transcription Factors
  • Serum Albumin
  • Rosiglitazone
  • Creatinine
  • Lisinopril
  • Nitric Oxide Synthase Type III
  • Nos3 protein, mouse
  • Janus Kinases
  • Renin